Skip To Main Content
Anna E. Marneth on Muck Rack

Anna E. Marneth

As seen in: Nature, Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Anna E. Marneth’s profile

Articles by Anna E. Marneth

Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing - Leukemia

|
By Jonas S. Jutzi, Edie I. Crosse, Chulwoo Kim, Charles Laurore, Benjamin Rolles, Frederike Kramer, Azucena Rocha, Mohammed Wazir, Lachelle D. Weeks, Joan How, Maximilian Stahl, Marlise R. Luskin, R. Coleman Lindsley, Olga Pozdnyakova, Sumit Rai, Timothy A Graubert, Robert Bradley, Ann Mullally, Anna E. Marneth, Bob van Gasteren, Anastasia Tishena
| Nature Verified
Abstract Somatic mutations in RNA splicing regulators, including the serine/arginine-rich protein SRSF2, are frequently observed in myeloid malignancies. Using mouse models and primary human samples, we investigated the impact of SRSF2 mutations on erythropoiesis. We found reduced erythropoiesis in Srsf2P95H versus wild-type mice upon stress-induced erythropoiesis and identified that SRSF2 mutations correlate with reduced hemoglobin in JAK2-mutant patients with myeloproliferative neoplasms (MPN).
Open in Who Shared Issue with article?

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms - Leukemia

|
By Benjamin Rolles, Nathan Fergusson, Jan Philipp Bewersdorf, Julia M Keating, Cecelia Perkins, Matthew Schwede, James England, Marlise R. Luskin, Daniel DeAngelo, Shai Shimony, Mifra Faiz, Addison C. Hillerbrand, Chulwoo Kim, Lachelle D. Weeks, Lauren Waldman, Mohammed Wazir, Joan How, Anna E. Marneth, Yiwen Liu, Martin J. Aryee, Raajit Rampal, Harrison K. Tsai, Jason Gotlib, Vikas Gupta, Maximilian Stahl, Ann Mullally
| Nature Verified
Abstract While TP53 mutations in myeloproliferative neoplasms (MPN) are associated with an increased risk of leukemic transformation, not all patients carrying a TP53 mutation progress. To better risk-stratify MPN patients with TP53 mutations, we analyzed data from 1540 patients treated at four specialized cancer centers. Among them, 1429 had wildtype TP53 and 111 had mutations in the TP53 gene.
Open in Who Shared Issue with article?

Mutations, inflammation and phenotype of myeloproliferative neoplasms

|
By Laboratoire d’Hématologie, CHU Nantes, Elisabeth Oppliger Leibundgut, Anna E. Marneth
| Frontiers
Sylvie Hermouet1,2* 1Nantes Université, INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France 2Laboratoire d’Hématologie, CHU Nantes, Nantes, France Knowledge on the myeloproliferative neoplasms (MPNs) – polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) – has accumulated since the discovery of the JAK/STAT-activating mutations associated with MPNs: JAK2V617F, observed in PV, ET and PMF; and the MPL and CALR mutations, found in...
Open in Who Shared Issue with article?

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response - Leukemia

|
By Jonas S. Jutzi, Anna E. Marneth, Benjamin Rolles, Shruti Bhatt, Samuel A. Myers, Peter van Galen, Fátima Al-Shahrour
| Nature Verified
Abstract Cancer is driven by somatic mutations that provide a fitness advantage. While targeted therapies often focus on the mutated gene or its direct downstream effectors, imbalances brought on by cell-state alterations may also confer unique vulnerabilities.
Open in Who Shared Issue with article?
Show More